Publications by authors named "J C Ansquer"
Background: Gout is a painful disorder and is common in type 2 diabetes. Fenofibrate lowers uric acid and reduces gout attacks in small, short-term studies. Whether fenofibrate produces sustained reductions in uric acid and gout attacks is unknown.
View Article and Find Full Text PDFObjective: To assess the efficacy of fenofibrate and statin dual therapy versus a double or equivalent dose of statin monotherapy.
Methods: A systematic literature search and meta-analysis was performed for publications before 1 January 2014 in MEDLINE, Embase, and BIOSIS Previews, among others.
Results: The difference in percentage change from baseline was in favor of dual therapy versus a double dose of statin monotherapy for triglycerides (difference -20%; standard error [SE] 2.
Purpose: Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies. The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing DME.
Methods: In this double-blind, randomized, placebo-controlled study, 110 subjects with DME not requiring immediate photocoagulation or intraocular treatment with adequate diabetes and blood pressure control received either fenofibric acid or placebo once daily for 1 year.
Article Synopsis
- Simvastatin and fenofibrate are commonly used together to treat dyslipidemia, but potential drug interactions have raised concerns about their simultaneous use.
- A study involving 85 healthy participants examined the effects of taking simvastatin either alone, together with fenofibrate at the same time, or at staggered intervals.
- Results showed minimal changes in the pharmacokinetics of simvastatin, suggesting that the interaction between these drugs is not clinically significant and allowing for their safe combined use, regardless of timing.
Purpose: Urinary peptidome changes and discrimination for potential renal glomerular and tubular damage after 6 wk of fenofibrate treatment were evaluated in 26 healthy subjects.
Experimental Design: Peptide profiling was performed in urine samples before and after treatment using high-resolution capillary electrophoresis coupled with electrospray ionization mass spectrometry.
Results: A panel of 88 fenofibrate-sensitive peptides was detected with a frequency of ≥50% before and after treatment.